Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Revenue of Alpine Immune Sciences, Inc. (ALPN)
Revenue in 2023 (TTM): $58.88 M
According to Alpine Immune Sciences, Inc.'s latest financial reports the company's current revenue (TTM) is $58.88 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Alpine Immune Sciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $58.88 M | $-22,028,000 | $-43,674,000 | $-32,081,000 | $-32,183,999 |
| 2022 | $30.06 M | $29.47 M | $-54,956,000 | $-55,432,000 | $-57,762,000 |
| 2021 | $23.44 M | $22.82 M | $-49,604,000 | $-50,420,000 | $-50,333,000 |
| 2020 | $9.34 M | $-17,850,000 | $-27,171,000 | $-27,946,000 | $-27,940,000 |
| 2019 | $1.74 M | $-34,107,000 | $-41,514,000 | $-41,852,000 | $-42,534,000 |
| 2018 | $705 K | $-28,265,000 | $-35,331,000 | $-36,853,000 | $-36,487,000 |
| 2017 | $1.73 M | $-8,895,000 | $-14,191,000 | $-7,983,000 | $-7,783,000 |
| 2016 | $2.95 M | $2.81 M | $-31,902,000 | $-31,463,000 | $-31,463,000 |
| 2015 | $492 K | $426 K | $-22,898,000 | $-22,818,000 | $-22,818,000 |
| 2014 | $ | $ | $-14,104,473 | $-15,036,012 | $-15,036,012 |
| 2013 | $ | $ | $-15,048,000 | $-16,198,000 | $-16,198,000 |
| 2012 | $ | $ | $-8,666,654 | $-9,572,760 | $-9,572,760 |